Does Wegovy cause weight loss — and how significant is the effect?

What the trial data actually showed

The clearest answer to whether Wegovy causes weight loss comes from STEP 1, a randomised, controlled trial of 1,961 adults with obesity or overweight plus at least one weight-related condition, none of whom had type 2 diabetes. After 68 weeks at the 2.4mg maintenance dose, participants lost an average of approximately 15% of starting body weight. Roughly one in three lost more than 20%. The placebo group, who received the same lifestyle support, lost about 2.4%. That's not a marginal difference.

These results informed the NICE recommendation for semaglutide (TA875), which recognised the medicine as clinically meaningful for appropriate adults. More recently, trials of the higher 7.2mg dose reported average weight loss of around 20.7% over 72 weeks, a figure that narrows the distance between Wegovy and tirzepatide considerably. If you want to understand how much weight loss Wegovy typically produces across different circumstances, the picture is genuinely variable by dose, duration and individual biology.

One practical habit worth building early: weigh yourself once a week, at the same time of day, on the same scales. Progress on Wegovy is rarely linear, and weekly snapshots are far more informative than daily readings that bounce with hydration.

How Wegovy produces its effect on appetite and food intake

Wegovy is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after eating, it tells your pancreas to release insulin, slows the movement of food through your stomach, and sends satiety signals to areas of the brain that regulate hunger. Semaglutide mimics this hormone but is engineered to stay active far longer: the natural molecule degrades in minutes; the drug lasts roughly a week, which is why one injection covers seven days.

The practical result is that most people find they feel full on noticeably smaller portions, snack less between meals, and lose interest in foods they previously craved. This isn't willpower; it's a pharmacological shift in how hunger is regulated. For a deeper look at the biology, the mechanism behind semaglutide and weight loss is covered in detail elsewhere on the site. The same pathway is explored from a slightly different angle in our piece on why semaglutide produces weight loss rather than simply reducing calories.

Wegovy is a GLP-1 agonist working through a single receptor pathway. Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors, which is one reason trials show larger average losses for tirzepatide. Neither is universally better for every person, clinical fit matters as much as headline percentages.

Who sees meaningful weight loss on Wegovy, and who may not

Results vary. Age, starting weight, metabolic health, adherence, and whether someone maintains the lifestyle changes recommended alongside treatment all influence outcomes. The STEP 1 figures are averages across a large trial population, some participants lost considerably more, some considerably less.

NICE's guidance notes that if someone has lost less than 5% of their starting weight after six months at the maintenance dose, continuing should be reviewed. That's a clinical decision made with a prescriber, not a reason to stop without discussion. The NHS medicines page for semaglutide gives a patient-level overview of what to expect and what to tell your prescribing team.

Wegovy is licensed for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Thresholds are adjusted downward by 2.5 kg/m² for some ethnic backgrounds under UK guidance. Pregnancy, breastfeeding, and trying to conceive are situations where Wegovy is not recommended; the same applies for anyone under 18. These aren't arbitrary restrictions, they reflect the populations studied in the licensing trials. Our semaglutide overview covers the full eligibility picture, and you can also read about how GLP-1 medicines as a class produce their effects.

Side effects that sometimes affect weight-loss progress

The most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion, and burping tend to cluster around the start of treatment or after a dose increase, then settle for most people within a couple of weeks. These effects are a direct consequence of the mechanism, slower gastric emptying means the stomach is fuller for longer, which can cause discomfort initially.

Persistent or severe abdominal pain that spreads to the back, with or without vomiting, should be assessed urgently, this is a recognised symptom of acute pancreatitis, which the MHRA highlighted in a Drug Safety Update for GLP-1 medicines in January 2026. It is uncommon, but serious enough to act on quickly. For a full account of what Wegovy causes beyond weight loss (including side effects by frequency) that page covers the territory carefully.

If you have questions about cost and what a private prescription through a regulated pharmacy includes, Wegovy pricing in the UK explains what is typically covered and why legitimate prices vary by provider. At nume, every treatment includes a free consultation reviewed by a GPhC-registered prescriber, free delivery, and 7-day aftercare, if that structure suits you, starting a free consultation is the next step.